Activating mutations in KRAS, as well as TP53 mutations, are the most frequently occurring mutations in human cancers, and are particularly prominent in human pancreatic ductal adenocarcinoma (PDAC). Here, TP53 is linked to pancreatic ductal adenocarcinoma.